These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 12944569)

  • 41. Discontinuation of prophylaxis against Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDS.
    El-Sadr WM; Burman WJ; Grant LB; Matts JP; Hafner R; Crane L; Zeh D; Gallagher B; Mannheimer SB; Martinez A; Gordin F
    N Engl J Med; 2000 Apr; 342(15):1085-92. PubMed ID: 10766581
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Beware of drug holidays before HIV salvage therapy.
    Hirschel B
    N Engl J Med; 2003 Aug; 349(9):827-8. PubMed ID: 12944566
    [No Abstract]   [Full Text] [Related]  

  • 43. Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up.
    ; Lundgren JD; Babiker A; El-Sadr W; Emery S; Grund B; Neaton JD; Neuhaus J; Phillips AN
    J Infect Dis; 2008 Apr; 197(8):1145-55. PubMed ID: 18476293
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interleukin-2 therapy in patients with HIV infection.
    ; ; Abrams D; Lévy Y; Losso MH; Babiker A; Collins G; Cooper DA; Darbyshire J; Emery S; Fox L; Gordin F; Lane HC; Lundgren JD; Mitsuyasu R; Neaton JD; Phillips A; Routy JP; Tambussi G; Wentworth D
    N Engl J Med; 2009 Oct; 361(16):1548-59. PubMed ID: 19828532
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Structured treatment interruption for patients with human immunodeficiency virus infection.
    Roca B
    N Engl J Med; 2003 Dec; 349(23):2268-9; author reply 2268-9. PubMed ID: 14657438
    [No Abstract]   [Full Text] [Related]  

  • 46. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.
    ; Lundgren JD; Babiker AG; Gordin F; Emery S; Grund B; Sharma S; Avihingsanon A; Cooper DA; Fätkenheuer G; Llibre JM; Molina JM; Munderi P; Schechter M; Wood R; Klingman KL; Collins S; Lane HC; Phillips AN; Neaton JD
    N Engl J Med; 2015 Aug; 373(9):795-807. PubMed ID: 26192873
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Short-course antiretroviral therapy in primary HIV infection.
    ; Fidler S; Porter K; Ewings F; Frater J; Ramjee G; Cooper D; Rees H; Fisher M; Schechter M; Kaleebu P; Tambussi G; Kinloch S; Miro JM; Kelleher A; McClure M; Kaye S; Gabriel M; Phillips R; Weber J; Babiker A
    N Engl J Med; 2013 Jan; 368(3):207-17. PubMed ID: 23323897
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection.
    Kozal M; Aberg J; Pialoux G; Cahn P; Thompson M; Molina JM; Grinsztejn B; Diaz R; Castagna A; Kumar P; Latiff G; DeJesus E; Gummel M; Gartland M; Pierce A; Ackerman P; Llamoso C; Lataillade M;
    N Engl J Med; 2020 Mar; 382(13):1232-1243. PubMed ID: 32212519
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis.
    Blanc FX; Sok T; Laureillard D; Borand L; Rekacewicz C; Nerrienet E; Madec Y; Marcy O; Chan S; Prak N; Kim C; Lak KK; Hak C; Dim B; Sin CI; Sun S; Guillard B; Sar B; Vong S; Fernandez M; Fox L; Delfraissy JF; Goldfeld AE;
    N Engl J Med; 2011 Oct; 365(16):1471-81. PubMed ID: 22010913
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Computer simulation of structured treatment interruption for HIV infection.
    Ferreira J; Hernandez-Vargas EA; Middleton RH
    Comput Methods Programs Biomed; 2011 Nov; 104(2):50-61. PubMed ID: 21899913
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti.
    Severe P; Juste MA; Ambroise A; Eliacin L; Marchand C; Apollon S; Edwards A; Bang H; Nicotera J; Godfrey C; Gulick RM; Johnson WD; Pape JW; Fitzgerald DW
    N Engl J Med; 2010 Jul; 363(3):257-65. PubMed ID: 20647201
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults.
    Schackman BR; Freedberg KA; Weinstein MC; Sax PE; Losina E; Zhang H; Goldie SJ
    Arch Intern Med; 2002 Nov; 162(21):2478-86. PubMed ID: 12437408
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Resistance, remission, and qualitative differences in HIV chemotherapy.
    Kirschner DE; Webb GF
    Emerg Infect Dis; 1997; 3(3):273-83. PubMed ID: 9284371
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection.
    Segal-Maurer S; DeJesus E; Stellbrink HJ; Castagna A; Richmond GJ; Sinclair GI; Siripassorn K; Ruane PJ; Berhe M; Wang H; Margot NA; Dvory-Sobol H; Hyland RH; Brainard DM; Rhee MS; Baeten JM; Molina JM;
    N Engl J Med; 2022 May; 386(19):1793-1803. PubMed ID: 35544387
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen.
    Izopet J; Massip P; Souyris C; Sandres K; Puissant B; Obadia M; Pasquier C; Bonnet E; Marchou B; Puel J
    AIDS; 2000 Oct; 14(15):2247-55. PubMed ID: 11089612
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097).
    Katlama C; Dominguez S; Gourlain K; Duvivier C; Delaugerre C; Legrand M; Tubiana R; Reynes J; Molina JM; Peytavin G; Calvez V; Costagliola D
    AIDS; 2004 Jan; 18(2):217-26. PubMed ID: 15075539
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of early versus deferred antiretroviral therapy for HIV on survival.
    Kitahata MM; Gange SJ; Abraham AG; Merriman B; Saag MS; Justice AC; Hogg RS; Deeks SG; Eron JJ; Brooks JT; Rourke SB; Gill MJ; Bosch RJ; Martin JN; Klein MB; Jacobson LP; Rodriguez B; Sterling TR; Kirk GD; Napravnik S; Rachlis AR; Calzavara LM; Horberg MA; Silverberg MJ; Gebo KA; Goedert JJ; Benson CA; Collier AC; Van Rompaey SE; Crane HM; McKaig RG; Lau B; Freeman AM; Moore RD;
    N Engl J Med; 2009 Apr; 360(18):1815-26. PubMed ID: 19339714
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antiretroviral therapy in HIV-infected patients with multidrug-resistant virus: applying the guidelines to practice.
    Kaplan SS; Mounzer KC
    AIDS Patient Care STDS; 2008 Dec; 22(12):931-40. PubMed ID: 19072099
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Structured treatment interruption in HIV-infected patients failing on multidrug therapy: is there a future for this strategy?
    Antinori A; Cingolani A; Perno CF
    AIDS; 2005 Oct; 19(15):1691-4. PubMed ID: 16184041
    [No Abstract]   [Full Text] [Related]  

  • 60. Results of antiretroviral treatment interruption and intensification in advanced multi-drug resistant HIV infection from the OPTIMA trial.
    Holodniy M; Brown ST; Cameron DW; Kyriakides TC; Angus B; Babiker A; Singer J; Owens DK; Anis A; Goodall R; Hudson F; Piaseczny M; Russo J; Schechter M; Deyton L; Darbyshire J;
    PLoS One; 2011 Mar; 6(3):e14764. PubMed ID: 21483491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.